Correspondence 0001193125-23-157490 from Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281) (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN) (CIK 0001404281)
Date: May 31, 2023 · CIK: 0001404281 · Accession: 0001193125-23-157490
AI Filing Summary & Sentiment
File numbers found in text: 333-272052
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission Washington, D.C. 20549-3628 Attention: Cindy Polynice Re: Request for Effectiveness for Eledon Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-272052)
Dear Ms. Polynice:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Eledon Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 10:00 a.m. Eastern Time, on Friday, June 2, 2023, or as soon thereafter as practicable. The Registrant respectfully requests that you notify Shelly Heyduk of O’Melveny & Myers LLP of such effectiveness by telephone at (949) 823-7968.
If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Heyduk at the telephone number above.
Very truly yours,
Eledon Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP May 31, 2023 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Cindy Polynice Re: Request for Effectiveness for Eledon Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-272052) Dear Ms. Polynice: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Eledon Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 10:00 a.m. Eastern Time, on Friday, June 2, 2023, or as soon thereafter as practicable. The Registrant respectfully requests that you notify Shelly Heyduk of O’Melveny & Myers LLP of such effectiveness by telephone at (949) 823-7968. If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Heyduk at the telephone number above. Very truly yours, Eledon Pharmaceuticals, Inc. By: /s/ Paul Little Name: Paul Little Title: Chief Financial Officer cc: Shelly Heyduk, O’Melveny & Myers LLP